P2Y12 antagonism: promises and challenges.

  title={P2Y12 antagonism: promises and challenges.},
  author={Alan D Michelson},
  journal={Arteriosclerosis, thrombosis, and vascular biology},
  volume={28 3},
The P2Y12 antagonist clopidogrel has a well-established role as an antithrombotic agent in the settings of percutaneous coronary intervention and acute coronary syndromes. However, several challenges remain, including the relatively slow onset of action of clopidogrel and the phenomenon of clopidogrel response variability or "resistance". Novel P2Y12 antagonists, including prasugrel, AZD6140, and cangrelor, have a faster onset of action, as well as more potent, and less variable, inhibition of… CONTINUE READING

From This Paper

Topics from this paper.


Publications citing this paper.
Showing 1-10 of 38 extracted citations

Purinergic mechanisms and pain--an update.

European journal of pharmacology • 2013
View 2 Excerpts

Similar Papers

Loading similar papers…